201 related articles for article (PubMed ID: 15636690)
1. Treatment options in Waldenstrom's macroglobulinemia.
Björkholm M
Clin Lymphoma; 2004 Dec; 5(3):155-62. PubMed ID: 15636690
[TBL] [Abstract][Full Text] [Related]
2. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Curr Treat Options Oncol; 2007 Apr; 8(2):144-53. PubMed ID: 17634838
[TBL] [Abstract][Full Text] [Related]
4. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
6. How we treat Waldenström's macroglobulinemia.
Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
[TBL] [Abstract][Full Text] [Related]
7. Waldenström's macroglobulinemia: a review of therapy.
Gertz MA
Leuk Lymphoma; 2002 Aug; 43(8):1517-26. PubMed ID: 12400593
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
9. Waldenström's macroglobulinemia.
Dimopoulos MA; Galani E; Matsouka C
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1351-66. PubMed ID: 10626154
[TBL] [Abstract][Full Text] [Related]
10. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
11. Waldenström's macroglobulinaemia.
Johnson SA; Oscier DG; Leblond V
Blood Rev; 2002 Sep; 16(3):175-84. PubMed ID: 12163003
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
[TBL] [Abstract][Full Text] [Related]
15. Waldenström's macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
17. Waldenström's macroglobulinemia: clinical features, complications, and management.
Dimopoulos MA; Panayiotidis P; Moulopoulos LA; Sfikakis P; Dalakas M
J Clin Oncol; 2000 Jan; 18(1):214-26. PubMed ID: 10623712
[TBL] [Abstract][Full Text] [Related]
18. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
